DGIdb - CC-223 Drug Record

CC-223 chembl:CHEMBL3545151 Antineoplastic

Alternate Names:

CC-223
ATG-008

Drug Info:

Pharmaceutical Developer	Celgene
Source Reported Drug Name(s)	CC-223
Drug Class	mTOR Inhibitor

(1 More Sources)

Publications:

Dumble et al., 2014, Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor., PLoS ONE
Mortensen et al., 2015, CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization., Mol. Cancer Ther.
Bendell et al., 2015, A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma., Cancer

CC-223 PIK3CA

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Phase I

PMIDs:
24978597 25855786 26177599

Sources:
JAX-CKB
CC-223 MTOR

Interaction Score: 0.37

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

Reported Cancer Type Lung

PMIDs:
None found

Sources:
ChemblInteractions CancerCommons TTD
CC-223 KRAS

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colon cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
24978597 25855786

Sources:
JAX-CKB
CC-223 PTEN

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Phase I

PMIDs:
26177599

Sources:
JAX-CKB

CancerCommons: CC-223
- Version: 25-July-2013
Alternate Names:

CC-223 Drug Trade Name

CC-223 Drug Development Name

Drug Info:

Drug Class mTOR Inhibitor

Source Reported Drug Name(s) CC-223

Pharmaceutical Developer Celgene

Publications:

JAX-CKB: CC-223

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Dumble et al., 2014, Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor., PLoS ONE

Mortensen et al., 2015, CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization., Mol. Cancer Ther.

Bendell et al., 2015, A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma., Cancer

TTD: CC-223
- Version: 2020.06.01
Alternate Names:

D05EXN TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL3545151
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL3545151
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	Advanced Solid Tumor
Response Type	sensitive
Approval Status	Phase I

Mechanism of Interaction	Serine/threonine-protein kinase mTOR inhibitor
Direct Interaction	yes
Reported Cancer Type	Lung

Indication/Tumor Type	colon cancer
Response Type	sensitive
Approval Status	Preclinical

CC-223	Drug Trade Name
CC-223	Drug Development Name

CC-223 Drug Record

CC-223 chembl:CHEMBL3545151 Antineoplastic

Alternate Names:

Drug Info:

Publications:

CC-223 PIK3CA

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type sensitive Approval Status Phase I

PMIDs: 24978597 25855786 26177599

Sources: JAX-CKB

CC-223 MTOR

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor Direct Interaction yes Reported Cancer Type Lung

PMIDs: None found

Sources: ChemblInteractions CancerCommons TTD

CC-223 KRAS

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colon cancer Response Type sensitive Approval Status Preclinical

PMIDs: 24978597 25855786

Sources: JAX-CKB

CC-223 PTEN

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type sensitive Approval Status Phase I

PMIDs: 26177599

Sources: JAX-CKB

CancerCommons: CC-223

Alternate Names: CC-223 Drug Trade Name CC-223 Drug Development Name

Drug Info: Drug Class mTOR Inhibitor Source Reported Drug Name(s) CC-223 Pharmaceutical Developer Celgene

Publications:

JAX-CKB: CC-223

Alternate Names:

Drug Info:

TTD: CC-223

Alternate Names: D05EXN TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL3545151

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL3545151

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Phase I

PMIDs:
24978597 25855786 26177599

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Serine/threonine-protein kinase mTOR inhibitor

Direct Interaction yes

Reported Cancer Type Lung

PMIDs:
None found

Sources:
ChemblInteractions CancerCommons TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colon cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
24978597 25855786

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Phase I

PMIDs:
26177599

Sources:
JAX-CKB

Alternate Names:

CC-223 Drug Trade Name

CC-223 Drug Development Name

Drug Info:

Drug Class mTOR Inhibitor

Source Reported Drug Name(s) CC-223

Pharmaceutical Developer Celgene

Alternate Names:

D05EXN TTD Drug ID